ICU Medical, Inc. (NASDAQ:ICUI) Given Consensus Rating of “Buy” by Brokerages

ICU Medical, Inc. (NASDAQ:ICUI) has been assigned an average rating of “Buy” from the nine analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $168.40.

ICUI has been the topic of several research reports. Needham & Company LLC upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a report on Wednesday, May 27th. BTIG Research assumed coverage on shares of ICU Medical in a research report on Monday, June 15th. They set a “buy” rating and a $170.00 target price for the company. KeyCorp lowered their target price on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating on the stock in a report on Monday, April 27th. Zacks Research raised shares of ICU Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 29th. Finally, Piper Sandler dropped their price target on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $154.97 on Friday. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. ICU Medical has a twelve month low of $107.00 and a twelve month high of $160.29. The stock’s 50 day moving average is $133.71 and its 200-day moving average is $138.59. The firm has a market capitalization of $3.87 billion, a price-to-earnings ratio of 83.77, a PEG ratio of 2.17 and a beta of 0.76.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.78 by $0.19. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The company had revenue of $525.77 million for the quarter, compared to analysts’ expectations of $520.65 million. During the same period last year, the business earned $1.72 EPS. ICU Medical’s quarterly revenue was down 12.3% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Sell-side analysts forecast that ICU Medical will post 6.5 EPS for the current fiscal year.

Insider Activity at ICU Medical

In other news, VP Virginia Ruth Sanzone sold 2,447 shares of the stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the sale, the vice president directly owned 19,460 shares of the company’s stock, valued at $2,414,596.80. This represents a 11.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the transaction, the director owned 7,960 shares in the company, valued at $978,363.60. This represents a 23.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Several large investors have recently bought and sold shares of the stock. AQR Capital Management LLC grew its position in ICU Medical by 2.5% in the 1st quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock worth $1,297,000 after purchasing an additional 229 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in ICU Medical by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier’s stock valued at $1,772,000 after buying an additional 560 shares during the last quarter. United Services Automobile Association bought a new position in shares of ICU Medical during the 1st quarter worth approximately $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of ICU Medical by 32.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier’s stock worth $9,472,000 after buying an additional 16,680 shares in the last quarter. Finally, Intech Investment Management LLC boosted its stake in shares of ICU Medical by 38.6% in the 1st quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier’s stock worth $1,658,000 after buying an additional 3,326 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.